Editorial scope: This guide addresses analytical evidence, documentation, and research-procurement literacy. Conclusions are limited to the records and methods discussed.

Start with the identity: DSIP and emideltide

Delta sleep-inducing peptide, usually shortened to DSIP, is the historical name for a nine-amino-acid sequence: tryptophan-alanine-glycine-glycine-aspartic acid-alanine-serine-glycine-glutamic acid. Emideltide is the international nonproprietary name associated with that sequence. FDA's substance database maps DSIP and delta sleep-inducing peptide to emideltide, but the database also states that a Unique Ingredient Identifier is an identity record—not evidence of regulatory review or approval.

The name alone does not completely define a research material. Emideltide free base and emideltide acetate are distinct bulk substances. FDA's 2026 review found that nomination records and commercial descriptions did not always make that distinction, and that historical publications often did not identify which form was studied. A literature finding cannot be transferred confidently when the test article and the present material are not chemically aligned.

This article evaluates published cell, animal, and human evidence without offering a dose, route, administration method, treatment recommendation, or research protocol. Supplier listings are discussed only as documentation records for laboratory procurement; they do not establish suitability for human or veterinary use.

  • DSIP: the historical descriptive name
  • Emideltide: the recognized nonproprietary name for the nine-residue peptide
  • Free base and acetate: related but distinct bulk substances
  • Supplier material: a separate lot that requires its own identity and quality evidence

The discovery is real, but the endogenous-peptide story remains unsettled

The original 1977 report described isolation of a peptide from rabbit cerebral venous blood and characterized a synthetic peptide with the same nine-residue sequence. In the reported rabbit experiments, material delivered directly into the brain increased delta-wave and spindle activity. That work supplied the sequence and the name that shaped the field.

Later research did not identify a clear precursor gene, biosynthetic pathway, or specific receptor for the proposed endogenous peptide. Immunoassays detected DSIP-like immunoreactivity in tissues and body fluids, but immunoreactivity is not necessarily proof that intact free DSIP is present: antibodies can recognize related structures, fragments, or associated molecules. One tissue study reported that a major DSIP-like immunoreactive peak did not co-elute with synthetic DSIP.

A 2006 review therefore described DSIP as an unresolved riddle and judged the sleep-factor hypothesis poorly documented. That does not erase the pharmacological experiments performed with synthetic emideltide. It means two questions must remain separate: what administered synthetic peptide did in an experiment, and whether the same sequence is an established naturally produced mammalian signaling peptide.

Cell and biochemical studies suggest mechanisms, not a validated receptor pathway

Biochemical studies have examined peptide degradation, aggregation, movement across barrier models, and interactions with opioid-related signaling. A bovine brain-microvessel cell study reported enzymatic metabolism of DSIP, while plasma and serum experiments found degradation and aggregation behavior that could contribute to variable experimental results.

Animal-tissue experiments suggested that opioid antagonism could block some DSIP-associated sleep or analgesia effects. Other work found that DSIP did not directly displace an opioid-receptor ligand, while experiments in neural tissue reported calcium-dependent release of enkephalins. Together, those findings support an indirect opioid-system hypothesis rather than proof that emideltide is itself a conventional opioid-receptor agonist.

No specific, independently validated DSIP receptor has emerged from this literature. Mechanistic language should therefore remain provisional. A supplier description that calls DSIP a neuropeptide or assigns it a single pathway is not a substitute for receptor-binding, functional, and replication evidence.

Animal sleep findings are biologically interesting and inconsistent

The original rabbit work and later rat and cat studies reported increases in delta-wave activity, non-rapid-eye-movement sleep, or total sleep under selected experimental conditions. A 1979 rat study reported longer sleep after systemic exposure, and a 1988 rat study linked DSIP-related interventions to slow-wave sleep and growth-hormone measurements.

Other experiments did not reproduce a selective delta-sleep effect, and some reported changes in both non-rapid-eye-movement and rapid-eye-movement sleep. Outcomes varied with species, preparation, experimental timing, route, analogue, and observation window. FDA's 2026 review explicitly noted contradictory animal findings and the lack of an explanation for them.

These studies support the narrow conclusion that synthetic DSIP can alter sleep-related physiology in some animal systems. They do not establish a consistent effect across models, an accepted mechanism, or a human clinical benefit. Direct-to-brain animal experiments are especially distant from ordinary supplier-material comparisons.

The first controlled human pilot was very small

A 1981 randomized, double-blind, placebo-controlled crossover pilot enrolled six healthy volunteers. The authors reported more sleep during a monitored daytime period and selected changes in subsequent nighttime sleep after emideltide, without the classic behavioral pattern of a sedative. The experiment was useful as an early human pharmacodynamic observation.

Six participants cannot provide a reliable estimate of benefit, uncommon adverse effects, subgroup differences, or durability. The study also assessed short-term physiological and behavioral measures rather than a clinical disorder. Its positive findings should be read as a small signal that motivated further work—not as treatment evidence.

FDA's later review also emphasized that the human literature generally did not identify the exact emideltide form consistently. That chemistry gap makes direct comparison with a modern free-base or acetate listing less certain.

Human insomnia studies produced mixed and weak results

Several small studies in people described as having chronic insomnia reported sleep-laboratory outcomes after emideltide. Some publications from the original research network described shorter sleep onset, improved sleep efficiency, or improved daytime performance. Important limitations included very small samples, unclear or inadequate control groups, externally matched healthy controls, and heterogeneous baseline characteristics.

Independent controlled studies were less encouraging. A 1987 double-blind crossover study reported some changes in sleep measures, but baseline imbalances complicated interpretation and the authors concluded that the improvement had little clinical significance. A 1992 double-blind placebo-controlled study of 16 participants found weak effects and concluded that short-term use was unlikely to provide major therapeutic benefit.

FDA's 2026 assessment judged the insomnia evidence inconclusive and, at best, preliminary. It found no information establishing long-term benefit and no study supporting the form and route proposed in the compounding nomination. The mixed results also show why a change in an electroencephalographic or sleep-stage variable is not automatically a clinically meaningful improvement.

Narcolepsy evidence is a single case, not a clinical program

The narcolepsy literature identified in FDA's review consisted of one single-subject report. A case can generate a hypothesis, but it cannot separate treatment effect from spontaneous variability, expectation, measurement noise, concurrent changes, or investigator judgment.

There are no replicated controlled trials establishing emideltide effectiveness for narcolepsy and no long-term evidence. FDA concluded that the single case was insufficient because of limited methodological rigor, potential recall bias, researcher subjectivity, and lack of external validity.

Calling DSIP a narcolepsy research compound should therefore describe only a historical research question. It should not be presented as evidence of an established mechanism or clinical option.

Withdrawal studies were uncontrolled and cannot establish effectiveness

Older reports explored DSIP during alcohol or opioid withdrawal, including a 1984 publication and a seven-person open trial published in 1998. The studies reported changes in subjective and objective withdrawal measures, but they lacked the randomized, blinded control structures needed to distinguish a peptide effect from the natural course of withdrawal, supportive care, expectation, participant selection, or measurement bias.

The reports also used different schedules and short observation periods. FDA found no study supporting the nominated form and route, and judged the available evidence insufficient even for the historical intravenous research setting. Professional guidelines reviewed by FDA did not discuss emideltide for withdrawal management.

These publications are part of the human evidence record, but their presence in PubMed does not turn an uncontrolled result into validated effectiveness. Serious clinical conditions require appropriately controlled evidence and product-specific safety data.

Safety is not established by small, short studies

The small insomnia studies reported few significant adverse effects, but their size and duration could not characterize uncommon or long-term risks. In the withdrawal literature, reported events included headache, nausea, vertigo, sweating, and episodes of hypotension. Interpretation was complicated because some symptoms could overlap with withdrawal itself.

FDA identified no clinical safety data for the form and route evaluated in the 2026 compounding review. It also found no adequate nonclinical toxicology program addressing genotoxicity, carcinogenicity, reproductive toxicity, chronic exposure, or addiction potential. An absence of reports in a passive surveillance search is not evidence that a sparsely used, unapproved substance is safe.

Peptide-related impurities, aggregates, and immunogenicity were additional concerns. Those risks depend on manufacturing and finished-product quality as well as nominal sequence. Historical tolerance of one study material cannot authenticate or qualify a current supplier lot.

FDA's 2026 review weighed against 503A Bulks List inclusion

FDA reviewed emideltide free base and emideltide acetate for possible inclusion on the section 503A Bulks List in connection with chronic insomnia, narcolepsy, and opioid withdrawal. The agency stated that neither substance has an applicable USP or National Formulary drug-substance monograph and neither is a component of an FDA-approved drug.

The review found identity and naming inconsistencies, incomplete characterization of impurities and aggregates, insufficient effectiveness evidence, and insufficient safety information. FDA proposed not adding either emideltide free base or emideltide acetate to the 503A Bulks List. The advisory committee process concerns whether a bulk substance may satisfy a specific compounding pathway; it is not an approval process for a peptide product.

A UNII, an international nonproprietary name, an FDA meeting, or a substance-registration entry must not be presented as FDA approval. As of the reviewed date, DSIP/emideltide is not an FDA-approved drug, and the 2026 assessment weighed against the requested compounding-list status.

Supplier documentation answers a different question from biological evidence

A research supplier can document what a lot appears to contain, but it cannot convert historical experiments into clinical evidence. For DSIP, documentation should define the sequence, terminal chemistry, free-base or salt form, expected molecular formula and mass, lot number, and test dates. Identity evidence and chromatographic purity evidence should be reported separately.

FDA's review of a nominator-submitted certificate noted testing for amino-acid composition, water, chromatographic purity, related substances, residual solvents, and mass-spectrometric identity, but also identified missing or inadequate controls for specific impurities, aggregates, and endotoxins. That illustrates why a high purity percentage is not a complete characterization package.

A supplier comparison can organize public prices and documents. It does not independently verify the sample, prove equivalence to a study article, establish sterility or safety, or demonstrate that the offered material has any human use. Those claims require different evidence.

  • Identity: observed mass or sequence evidence linked to the lot
  • Form: free peptide, acetate, or another explicitly defined material
  • Purity: method, chromatogram, integration context, and result
  • Content: a quantitative assay distinct from area-percent purity
  • Additional attributes: water, counterions, residual solvents, aggregates, endotoxin, and stability when relevant

Evidence-stage summary

Cell and biochemical evidence: synthetic DSIP has been studied for degradation, aggregation, barrier transport, and indirect opioid-system effects. No specific receptor or accepted endogenous signaling pathway has been established.

Animal evidence: multiple experiments reported sleep-related EEG or behavioral changes, while others produced conflicting results. Species, experimental design, timing, and material differences limit synthesis.

Human evidence: a six-person healthy-volunteer pilot and several small insomnia studies produced mixed findings. Narcolepsy evidence is limited to one case, and withdrawal reports were uncontrolled. There is no modern confirmatory clinical program establishing effectiveness or long-term safety.

Regulatory and supplier evidence: substance naming records and certificates can support identity or documentation review, but they are not approval, clinical validation, or proof that a commercial lot matches historical research material.

FAQ: Is DSIP the same molecule as emideltide?

DSIP is the historical descriptive name, and emideltide is the recognized nonproprietary name mapped to the same nine-amino-acid sequence. A product still needs to specify whether it contains the free peptide, acetate, or another form because those are not interchangeable descriptions of one bulk substance.

FAQ: Does DSIP have a proven sleep benefit in humans?

No proven clinical benefit has been established. Small historical studies reported mixed sleep findings, and two controlled insomnia studies found weak, clinically limited, or inconclusive effects. FDA's 2026 review judged the evidence preliminary and insufficient.

FAQ: Does an FDA UNII mean DSIP is approved?

No. A Unique Ingredient Identifier helps identify a substance in regulatory data systems. FDA explicitly states that UNII availability does not imply regulatory review or approval. DSIP/emideltide is not an FDA-approved drug.

Sources and further reading

Primary and standards-based sources used to frame this educational overview:

Explore related resources

Peptide Due Diligence Research Brief

Keep the evidence in view.

Receive concise briefings on analytical testing, documentation quality, supplier transparency, and new additions to the research library.

By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.

Already subscribed? Get your free field guide.

Continue your due diligence